SCHEMBL4898519

SCHEMBL4898519

O=C(O)c1ccc(-c2cn(-c3ccccc3)c(=O)n2Cc2ccc(CP(=O)(OF)OF)c(Br)c2)cc1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.34
MAPK10 P53779 1/20 0.34
RHEB Q15382 2/20 0.34
MCHR1 Q99705 1/20 0.34
MAPT P10636 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPK8 P45983 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MMP13 P45452 1/20 0.32
SLC22A8 Q8TCC7 1/20 0.32
GCGR P47871 1/20 0.31
GIPR P48546 1/20 0.31
SSTR5 P35346 1/20 0.31
PPARG P37231 1/20 0.31
CMA1 P23946 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898658 0.92 MAPK8 (0.38) ALDH1A1MAPK10MAPTSMN1; SMN2MAPK8
SCHEMBL4895489 0.89 ALDH1A1 (0.39) ALDH1A1MAPK10RHEBMCHR1MAPK8
SCHEMBL4898669 0.89 ALDH1A1 (0.39) ALDH1A1MAPK10RHEBMCHR1MAPK8
SCHEMBL4898625 0.88 KDM4E (0.37) ALDH1A1MAPK10RHEBMCHR1KDM4E
SCHEMBL4901306 0.88 ALDH1A1 (0.39) ALDH1A1MAPK10RHEBMCHR1MAPT
SCHEMBL4901698 0.87 ALDH1A1 (0.38) ALDH1A1MAPK10RHEBMCHR1MAPT
SCHEMBL4889733 0.84 ALDH1A1 (0.38) ALDH1A1MAPK10RHEBMCHR1MAPT
SCHEMBL4891960 0.84 GCGR (0.34) ALDH1A1MAPK10RHEBMCHR1GCGR
SCHEMBL4901272 0.84 KDM4E (0.35) ALDH1A1MAPK10RHEBMAPTMEN1
SCHEMBL4898674 0.82 ALDH1A1 (0.38) ALDH1A1MAPK10RHEBMMP13PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US claimed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS ALDH1A1 3704/4885MAPK10 656/4885RHEB 1672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.